News
BeiGene Aktie: Dossier zur Marktlage
Die BeiGene Aktie verzeichnete in den letzten Tagen einen moderaten Rückgang und liegt aktuell bei 234,00 Euro, was einem Minus von 4,10 Prozent innerhalb der letzten Woche entspricht. Dieser
Merck Stock: Strategic $2B Chinese Partnership Boosts Portfolio
Merck & Co. has entered a landmark licensing agreement with Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral inhibitor targeting lipoprotein(a) formation for
Merck Stock: Strategic $2B Chinese Partnership Boosts Portfolio
Merck & Co. has entered a landmark licensing agreement with Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral inhibitor targeting lipoprotein(a) formation for
Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow
In a market obsessed with the next big growth story, it’s easy to overlook the quiet power of consistency. As tariff turbulence continues, some investors are diverting a portion of their portfolio
Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow
In a market obsessed with the next big growth story, it’s easy to overlook the quiet power of consistency. As tariff turbulence continues, some investors are diverting a portion of their portfolio
EQS-News: Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm
EQS-News: Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm
Santhera informiert am Capital Markets Day über den aktuellen Stand der kommerziellen Einführung von AGAMREE® und zukünftige strategische Prioritäten
Pratteln, Schweiz, 24. März 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Unternehmen an seinem heutigen Capital Markets Day (CMD) in Zürich über die kommerziellen Fortschritte
Bayer AG Stock: $2.1 Billion Glyphosate Verdict Intensifies Pressure
A severe setback in ongoing glyphosate litigation has further strained Bayer AG's financial outlook, as a Georgia jury ordered the troubled German pharmaceutical giant to pay approximately $2.1
Bayer AG Stock: $2.1 Billion Glyphosate Verdict Intensifies Pressure
A severe setback in ongoing glyphosate litigation has further strained Bayer AG's financial outlook, as a Georgia jury ordered the troubled German pharmaceutical giant to pay approximately $2.1
Bayer AG Stock: $2.1 Billion Roundup Verdict Hits Hard
Bayer AG faces a significant new legal setback as a Georgia jury has ordered the German pharmaceutical and agrochemical giant to pay approximately $2.1 billion (€1.9 billion) in damages over claims
Bayer AG Stock: $2.1 Billion Roundup Verdict Hits Hard
Bayer AG faces a significant new legal setback as a Georgia jury has ordered the German pharmaceutical and agrochemical giant to pay approximately $2.1 billion (€1.9 billion) in damages over claims
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
AbbVie Inc. (NYSE: ABBV) is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement
AbbVie Stock: Legal Battle Weighs on Share Price
AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00
Bristol-Myers Squibb Aktie: Optimismus prägt Strategie
Die Bristol-Myers Squibb Aktie zeigt sich derzeit in solider Verfassung. Der Kurs des Biopharmazie-Riesen kletterte auf 61,04 USD (Stand: 22. März 2025), was einem Anstieg von 1,01% zum Vortag
Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth
Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous
Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth
Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous
Alnylam Stock: FDA Approves Amvuttra for Rare Heart Disease
Alnylam Pharmaceuticals has secured a significant victory with the FDA's approval to expand Amvuttra's (vutrisiran) use for treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare and
Biomarin Pharmaceutical Stock: Strong Data Boosts Outlook
Biomarin Pharmaceutical recently presented compelling new data for its key medications VOXZOGO and PALYNZIQ at the American College of Medical Genetics and Genomics annual meeting, sparking investor
Johnson & Johnson Stock: Cancer Breakthroughs Amidst Market Challenges
Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears
Johnson & Johnson Stock: Cancer Breakthroughs Amidst Market Challenges
Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears
EQS-News: Eckert & Ziegler und AtomVie Global Radiopharma unterzeichnen weltweite Vereinbarung über die Lieferung von Lutetium-177
EQS-News: Eckert & Ziegler und AtomVie Global Radiopharma unterzeichnen weltweite Vereinbarung über die Lieferung von Lutetium-177
Natera Stock: Insider Sales Amid Strong Financial Growth
Executives at molecular diagnostics company Natera have recently sold shares worth over $1.2 million, even as the company demonstrates impressive market performance. Board Chairman Matthew
ANI Stock: Nitazoxanide Tablets Launch Boosts Market Position
ANI Pharmaceuticals, a diversified biopharmaceutical company valued at $1.3 billion, has announced the launch of 500mg Nitazoxanide tablets, a generic version of reference drug Alinia®. This